Danthron
As of the edition of 20 October 2026, Danthron is a small molecule: marketed, first approved in 1994 (UK); acts on RXRA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1994
- Kind
- Small molecule
- First approved
- 19 October 1994 (UK)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Napp Pharmaceuticals
- Withdrawn from market
- 1 January 1988 (in some regions)
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Danthron.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| RXRA | Retinoic acid receptor RXR-alpha | P19793 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Napp Pharmaceuticals | Originator | 1994 to now |